TMBR

TMBR - Timber Pharmaceuticals, Inc. Stock Price, Fair Value and News

00
Market Closed as of 31 Jan 2024, 04:00 pm ET

TMBR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TMBR Price Action

TMBR RSI Chart

TMBR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TMBR Valuation

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TMBR Fundamentals

TMBR Revenue

TMBR Earnings

TMBR Profitability

TMBR Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2022929.0K540.2K273.2K83.2K
2021467.6K856.5K798.9K886.5K
2020302.4K297.4K404.4K453.8K
201957.0K-256.6K285.5K
201873.0K72.0K79.0K71.0K
2017100.0K86.0K84.0K69.0K
201664.0K93.0K107.0K120.0K
2015----
TMBR
Timber Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for orphan dermatologic diseases. The company's lead product candidates include TMB-001, a patented topical formulation of isotretinoin that has completed Phase 2b clinical trial for the treatment of moderate to severe subtypes of CI, a group of rare genetic keratinization disorders; and TMB-003, a proprietary formulation of Sitaxsentan, which is a selective endothelin-A receptor antagonist that is in preclinical development for the treatment of sclerotic skin diseases. It is also involved in the development of BPX-01, which is in Phase 3 topical minocycline for the treatment of inflammatory lesions of acne vulgaris; and BPX-04 that is a Phase 3 ready topical minocycline for the treatment of papulopustular rosacea. The company was founded in 2019 and is headquartered in Warren, New Jersey.
 CEO
 WEBSITEtimberpharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES9